Glossopharyngeal Dystonia Secondary to a Lurasidone-Fluoxetine CYP-3A4 Interaction

Paul, Sean; Cooke, Brian K.; Nguyen, Mathew

doi:10.1155/2013/136194

Cited by 6 publications

(7 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Concurrent medications with D2 receptor antagonist effects (antipsychotics and 1 case of metoclopramide) were reported in 25.9% of cases. 52,57,59,62,68,70,73 Of these, the majority occurred when the dopamine receptor antagonist was added to antidepressant treatment. Cases were evenly distributed by gender and occurred in patients with a wide age range (12-78 years).…”

Section: Dystonia Casesmentioning

confidence: 99%

Extrapyramidal Reactions Associated With Serotonergic Antidepressants

Hawthorne

Caley

2015

Ann Pharmacother

View full text Add to dashboard Cite

show abstract

Section: Dystonia Casesmentioning

confidence: 99%

Extrapyramidal Reactions Associated With Serotonergic Antidepressants

Hawthorne

Caley

2015

Ann Pharmacother

View full text Add to dashboard Cite

show abstract

“…A recent case report documented the occurrence of a glossopharyngeal dystonia following coadministration of fluoxetine with lurasidone [47]. This effect was attributed to the inhibitory action of fluoxetine and norfluoxetine on CYP3A4-mediated biotransformation of lurasidone.…”

Section: {{{mentioning

confidence: 99%

Clinically relevant interactions between newer antidepressants and second-generation antipsychotics

Spina

León

2014

Expert Opinion on Drug Metabolism & Toxicology

View full text Add to dashboard Cite

More PK DI studies are needed to better establish dose correction factors after adding fluoxetine and paroxetine to aripiprazole, iloperidone and risperidone. Further PK DI studies and case reports are also needed to better establish the need for dose correction factors after adding i) fluoxetine to clozapine, lurasidone, quetiapine and olanzapine; ii) paroxetine to olanzapine; iii) fluvoxamine to asenapine, aripiprazole, iloperidone, lurasidone, olanzapine, quetiapine and risperidone; iv) high sertraline doses to aripiprazole, clozapine, iloperidone and risperidone: v) bupropion and duloxetine to aripiprazole, clozapine, iloperidone and risperidone; and vi) asenapine to paroxetine and venlafaxine. Possible beneficial PD DI effects occur after adding SGAs to newer antidepressants for treatment-resistant major depressive and obsessive-compulsive disorders. The lack of studies combining newer antidepressants and SGAs in psychotic depression is worrisome. PD DIs between newer antidepressants and SGAs may be more likely for mirtazapine and bupropion. Adding selective serotonin reuptake inhibitors and SGAs may increase QTc interval and may very rarely contribute to torsades de pointes.

show abstract

“…Lurasidone had shown good efficacy in schizophrenia as well as bipolar disorder. [ 1 2 ] It has similar affinity for the dopamine D2 and serotonin 5-HT2A receptors and a much greater affinity for 5-HT7, 5-HT1A, and a2C-adrenergic subtype receptors than other atypical antipsychotics. As antagonism of 5-HT7 can improve cognition, memory, and mood symptoms, lurasidone is preferred in many clinical situations above other SGAs.…”

mentioning

confidence: 99%

“…It could be due to high receptor affinity in a particular person and specific genetic variants. [ 2 3 ]…”

mentioning

confidence: 99%